

SGLT2 INHIBITOR / GLP-1 RA ASSOCIATED EUGLYCEMIC DKA

SGLT2i= sodium glucose transport inhibitor. GLP-1 RA= glucagon like peptide 1 receptor agonist. DKA= diabetic ketoacidosis.

Background


- Acknowledged risk of eDKA with SGLT2i use
- Sporadic case reports of eDKA with GLP-1 RA use
- Increased use of SGLT2i and GLP-1 RA for non DM indications
- Newer guidelines support SGLT2i + GLP-1 RA for some DM patients (synergistic effect)

Clinical Observation


Noticeable trend of euglycemic DKA (eDKA) occurring in multiple patients who had been treated with both an SGLT2i as well as a GLP-1 RA simultaneously.

Q: Does the concomitant use of both classes of medications increase the risk of euglycemic DKA?


Methodology–Retrospective Case Series



Descriptive Analysis



Management




Outcomes

P1
Delayed recovery; required addition of TPN.
Was there an element of starvation ketosis?

P3
Cleared DKA, then developed severe lactic acidosis with multi-organ failure and did not survive.

Participants 2, 4–11 recovered and discharged home with no lasting effects.

Next Steps– Phase Two: Multicenter Statistical Analysis



This project was determined to be exempt by the IRB at the University of Maryland, Baltimore.

REFERENCES:

- Juneja D, Nasa P, Jain R, Singh O. Sodium-glucose cotransporter-2 inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports. World J Diabetes. 2023;14(8):1314–1322.
- Jardiance. Prescribing information. Boehringer Ingelheim Pharmaceuticals; 2023. Accessed December 25, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf
- Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology. 2025;13(1):15–28.
- Niu M, Fan Y, Zhang Y, et al. Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system. Front Pharmacol. 2024;15:1414268.
- Gourdy P, Darmon P, Dievart F, et al. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 2023;22(1):79.